| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036715545 |
| P356 | DOI | 10.1038/GT.2009.80 |
| P698 | PubMed publication ID | 19626053 |
| P5875 | ResearchGate publication ID | 26689451 |
| P2093 | author name string | H J Lee | |
| B G Kim | |||
| I H Park | |||
| S U Kim | |||
| D H Hwang | |||
| J I Seok | |||
| I S Joo | |||
| P2860 | cites work | Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. | Q45879717 |
| Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. | Q46817719 | ||
| Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration | Q46965352 | ||
| Low levels of the vascular endothelial growth factor in CSF from early ALS patients. | Q47376496 | ||
| VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model | Q47427098 | ||
| Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. | Q48199408 | ||
| Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage | Q48244314 | ||
| Effect of new O-superfamily conotoxin SO3 on sodium and potassium currents of cultured hippocampal neurons. | Q48385868 | ||
| Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. | Q51659718 | ||
| Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. | Q54622823 | ||
| Stem cell therapy in human ALS | Q56929793 | ||
| Vascular endothelial growth factor counteracts the loss of phospho-Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis | Q57244943 | ||
| Intrathecal morphine in mice: a new technique | Q71852099 | ||
| Stem cells for Parkinson disease and ALS: replacement or protection? | Q76390308 | ||
| Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression | Q80673128 | ||
| Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients | Q80729597 | ||
| Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation | Q22004269 | ||
| VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection | Q24302846 | ||
| Stem cells for the treatment of neurological disorders | Q28249501 | ||
| Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells | Q28570673 | ||
| Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 | ||
| Neurotrophins and their receptors: a convergence point for many signalling pathways | Q29616108 | ||
| Directed differentiation of embryonic stem cells into motor neurons | Q29616200 | ||
| Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator | Q29619043 | ||
| Amyotrophic lateral sclerosis | Q29619516 | ||
| Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats | Q30581117 | ||
| Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice | Q33698123 | ||
| Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations | Q34458377 | ||
| Molecular and cellular pathways of neurodegeneration in motor neurone disease | Q35489359 | ||
| Stem-cell therapy for amyotrophic lateral sclerosis. | Q35832769 | ||
| Targets for vascular protection after acute ischemic stroke | Q35850986 | ||
| Human neural stem cells genetically modified for brain repair in neurological disorders | Q35918287 | ||
| Randomized control trials in ALS: lessons learned | Q35932089 | ||
| Gene-based treatment of motor neuron diseases | Q36288219 | ||
| Stem cell-based cell therapy for spinal cord injury | Q36893915 | ||
| Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model | Q40184078 | ||
| Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease | Q40278367 | ||
| GDNF delivery using human neural progenitor cells in a rat model of ALS. | Q40425197 | ||
| Fate of immortalized human neuronal progenitor cells transplanted in rat spinal cord. | Q40458312 | ||
| Functional properties of motoneurons derived from mouse embryonic stem cells. | Q40517622 | ||
| Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease | Q40543499 | ||
| Arteriogenesis Induced by Intramyocardial Vascular Endothelial Growth Factor 165 Gene Transfer in Chronically Ischemic Pigs | Q44592507 | ||
| Growth factors and nonparenchymal cell conditioned media induce mitogenic responses in stable long-term adult rat hepatocyte cultures | Q44732718 | ||
| Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. | Q44816539 | ||
| Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. | Q45076564 | ||
| Entrance in mitosis of adult cardiomyocytes in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer | Q45856834 | ||
| Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep | Q45857099 | ||
| VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death | Q45863485 | ||
| Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse | Q45869109 | ||
| Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. | Q45877621 | ||
| P433 | issue | 10 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| neural stem cell | Q2944097 | ||
| overexpression | Q61643320 | ||
| P304 | page(s) | 1234-1244 | |
| P577 | publication date | 2009-07-23 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice | |
| P478 | volume | 16 |
| Q37400451 | ALS and oxidative stress: the neurovascular scenario |
| Q36111849 | Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient? |
| Q34109028 | Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. |
| Q34595662 | Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era. |
| Q39946077 | Cell-Based Neurorestorotherapy in Amyotrophic Lateral Sclerosis - Scientific Truth should Rely on Facts, but Not Conjecture |
| Q34478634 | Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future |
| Q42685032 | Current and emerging treatments for amyotrophic lateral sclerosis |
| Q37871429 | Current challenges for the advancement of neural stem cell biology and transplantation research. |
| Q38210852 | Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery |
| Q49015193 | Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease |
| Q38157505 | Gene and protein therapies utilizing VEGF for ALS. |
| Q33638440 | Human motor neurons generated from neural stem cells delay clinical onset and prolong life in ALS mouse model |
| Q33614725 | Human nerual stem cells for brain repair |
| Q39360374 | Human neural stem cells genetically modified to express human nerve growth factor (NGF) gene restore cognition in the mouse with ibotenic acid-induced cognitive dysfunction |
| Q37184529 | Human neural stem cells genetically modified to overexpress Akt1 provide neuroprotection and functional improvement in mouse stroke model |
| Q39338787 | Human neural stem cells overexpressing choline acetyltransferase restore cognitive function of kainic acid-induced learning and memory deficit animals. |
| Q38986711 | Human olfactory bulb neural stem cells expressing hNGF restore cognitive deficit in Alzheimer's disease rat model |
| Q38302028 | Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease |
| Q91688794 | Influence of Lineage-Negative Stem Cell Therapy on Articulatory Functions in ALS Patients |
| Q46264839 | Intracranial transplant of olfactory ensheathing cells can protect both upper and lower motor neurons in amyotrophic lateral sclerosis |
| Q58278823 | Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats |
| Q35865916 | Isolation of Human Neural Stem Cells from the Amniotic Fluid with Diagnosed Neural Tube Defects |
| Q48454588 | Localization and differentiation pattern of transplanted human multipotent mesenchymal stromal cells in the brain of bulbectomized mice. |
| Q39028991 | Long-term survival and differentiation of human neural stem cells in nonhuman primate brain with no immunosuppression |
| Q39137284 | Neural stem cell-based gene therapy for brain tumors |
| Q38079295 | Neural stem cell-based treatment for neurodegenerative diseases |
| Q34222849 | Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy |
| Q50904589 | Neuroprotective Effect of Human Adipose Stem Cell-Derived Extract in Amyotrophic Lateral Sclerosis. |
| Q33985590 | Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? |
| Q92778200 | Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients |
| Q34095561 | Optimal time for subarachnoid transplantation of neural progenitor cells in the treatment of contusive spinal cord injury |
| Q92712171 | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates |
| Q88405456 | Pharmacological approaches promoting stem cell-based therapy following ischemic stroke insults |
| Q27338320 | Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis |
| Q36117618 | Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application |
| Q38024220 | Recent preclinical evidence advancing cell therapy for Alzheimer's disease. |
| Q33616384 | Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis |
| Q52558375 | Safety and Feasibility of Lin- Cells Administration to ALS Patients: A Novel View on Humoral Factors and miRNA Profiles. |
| Q35212423 | Spinal vascular endothelial growth factor induces phrenic motor facilitation via extracellular signal-regulated kinase and Akt signaling. |
| Q37851503 | Stem cell technology for the study and treatment of motor neuron diseases. |
| Q26995278 | Stem cell transplantation for motor neuron disease: current approaches and future perspectives |
| Q37761366 | Stem cells and the ALS neurologist |
| Q34482689 | Stem cells for spinal cord regeneration: Current status |
| Q27687068 | Stem cells in human neurodegenerative disorders--time for clinical translation? |
| Q39471822 | Suppression of Etk/Bmx protects against ischemic brain injury |
| Q48460372 | Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy |
| Q37811420 | The Role of GLP-1 in Neuronal Activity and Neurodegeneration |
| Q37848076 | The role of mitochondria in brain aging and the effects of melatonin |
| Q59001351 | Translational Research in Stem Cell Treatment of Neuromuscular Diseases |
| Q50351327 | Transplantation of Recombinant Vascular Endothelial Growth Factor (VEGF)189-Neural Stem Cells Downregulates Transient Receptor Potential Vanilloid 1 (TRPV1) and Improves Motor Outcome in Spinal Cord Injury. |
| Q44315043 | Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model |
| Q26825854 | Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury |
| Q36939729 | Use of a Human Artificial Chromosome for Delivering Trophic Factors in a Rodent Model of Amyotrophic Lateral Sclerosis |
| Q35225943 | Vascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patients |
| Q38882640 | Vascular endothelial growth factor: a neurovascular target in neurological diseases |
Search more.